Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Hutchison China MediTech stock

Own Hutchison China MediTech stock in just a few minutes.

Fact checked

Hutchison China MediTech Limited is a biotechnology business based in the US. Hutchison China MediTech shares (HCM) are listed on the NASDAQ and all prices are listed in US Dollars. Hutchison China MediTech employs 853 staff and has a trailing 12-month revenue of around USD$209.5 million.

How to buy shares in Hutchison China MediTech

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Hutchison China MediTech. Find the stock by name or ticker symbol: HCM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Hutchison China MediTech reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Hutchison China MediTech, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Hutchison China MediTech. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Hutchison China MediTech share price

Use our graph to track the performance of HCM stocks over time.

Hutchison China MediTech shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$14.74 - USD$37
50-day moving average USD$34.4232
200-day moving average USD$32.3768
Wall St. target priceUSD$39.6
PE ratio 17.6909
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.66

Buy Hutchison China MediTech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Hutchison China MediTech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Hutchison China MediTech under- or over-valued?

Valuing Hutchison China MediTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Hutchison China MediTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Hutchison China MediTech's P/E ratio

Hutchison China MediTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Hutchison China MediTech shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Hutchison China MediTech financials

Revenue TTM USD$209.5 million
Gross profit TTM USD$-93,452,000
Return on assets TTM -18.68%
Return on equity TTM -29.31%
Profit margin -52.68%
Book value $2.49
Market capitalisation USD$4.5 billion

TTM: trailing 12 months

Shorting Hutchison China MediTech shares

There are currently 831,246 Hutchison China MediTech shares held short by investors – that's known as Hutchison China MediTech's "short interest". This figure is 15.7% down from 985,637 last month.

There are a few different ways that this level of interest in shorting Hutchison China MediTech shares can be evaluated.

Hutchison China MediTech's "short interest ratio" (SIR)

Hutchison China MediTech's "short interest ratio" (SIR) is the quantity of Hutchison China MediTech shares currently shorted divided by the average quantity of Hutchison China MediTech shares traded daily (recently around 225882.06521739). Hutchison China MediTech's SIR currently stands at 3.68. In other words for every 100,000 Hutchison China MediTech shares traded daily on the market, roughly 3680 shares are currently held short.

However Hutchison China MediTech's short interest can also be evaluated against the total number of Hutchison China MediTech shares, or, against the total number of tradable Hutchison China MediTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hutchison China MediTech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Hutchison China MediTech shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Hutchison China MediTech shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hutchison China MediTech.

Find out more about how you can short Hutchison China MediTech stock.

Hutchison China MediTech share dividends

We're not expecting Hutchison China MediTech to pay a dividend over the next 12 months.

Have Hutchison China MediTech's shares ever split?

Hutchison China MediTech's shares were split on 30 May 2019.

Hutchison China MediTech share price volatility

Over the last 12 months, Hutchison China MediTech's shares have ranged in value from as little as $14.74 up to $37. A popular way to gauge a stock's volatility is its "beta".

HCM.US volatility(beta: 0.59)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hutchison China MediTech's is 0.5915. This would suggest that Hutchison China MediTech's shares are less volatile than average (for this exchange).

Hutchison China MediTech overview

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site